1
|
Ya. Zakharova L, Vasilieva EA, Mirgorodskaya AB, Zakharov SV, Pavlov RV, Kashapova NE, Gaynanova GA. Hydrotropes: solubilization of nonpolar compounds and modification of surfactant solutions. J Mol Liq 2022. [DOI: 10.1016/j.molliq.2022.120923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
|
2
|
Paul R, Chattaraj KG, Paul S. Role of Hydrotropes in Sparingly Soluble Drug Solubilization: Insight from a Molecular Dynamics Simulation and Experimental Perspectives. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2021; 37:4745-4762. [PMID: 33853331 DOI: 10.1021/acs.langmuir.1c00169] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Drug molecules' therapeutic efficacy depends on their bioavailability and solubility. But more than 70% of the formulated drug molecules show limited effectiveness due to low water solubility. Thus, the water solubility enhancement technique of drug molecules becomes the need of time. One such way is hydrotropy. The solubilizing agent of a hydrophobic molecule is generally referred to as a hydrotrope, and this phenomenon is termed hydrotropy. This method has high industrial demand, as hydrotropes are noninflammable, readily available, environmentally friendly, quickly recovered, cost-effective, and not involved in solid emulsification. The endless importance of hydrotropes in industry (especially in the pharmaceutical industry) motivated us to prepare a feature article with a clear introduction, detailed mechanistic insights into the hydrotropic solubilization of drug molecules, applications in pharma industries, and some future directions of this technique. Thus, we believe that this feature article will become an adequate manual for the pharmaceutical researchers who want to explore all of the past perspectives of the hydrotropic action of hydrotropes in pharmaceutics.
Collapse
Affiliation(s)
- Rabindranath Paul
- Department of Chemistry, Indian Institute of Technology, Guwahati, Assam 781039, India
| | | | - Sandip Paul
- Department of Chemistry, Indian Institute of Technology, Guwahati, Assam 781039, India
| |
Collapse
|
3
|
Malliappan SP, Kandasamy P, Chidambaram S, Venkatasubbu D, Perumal SK, Sugumaran A. Breast Cancer Targeted Treatment Strategies: Promising Nanocarrier Approaches. Anticancer Agents Med Chem 2019; 20:1300-1310. [PMID: 31642415 DOI: 10.2174/1871520619666191022175003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 08/20/2019] [Accepted: 08/20/2019] [Indexed: 12/18/2022]
Abstract
Breast cancer is the second most common cancer that causes death among women worldwide. Incidence of breast cancer is increasing worldwide, and the age at which breast cancer develops has shifted from 50- 70 years to 30-40 years. Chemotherapy is the most commonly used effective treatment strategy to combat breast cancer. However, one of the major drawbacks is low selective site-specificity and the consequent toxic insult to normal healthy cells. The nanocarrier system is consistently utilised to minimise the various limitations involved in the conventional treatment of breast cancer. The nanocarrier based targeted drug delivery system provides better bioavailability, prolonged circulation with an effective accumulation of drugs at the tumour site either by active or passive drug targeting. Active targeting has been achieved by receptor/protein anchoring and externally guided magnetic nanocarriers, whereas passive targeting accomplished by employing the access to the tunnel via leaky tumour vasculature, utilising the tumour microenvironment, because the nanocarrier systems can reduce the toxicity to normal cells. As of now a few nanocarrier systems have been approved by FDA, and various nanoformulations are in the pipeline at the preclinical and clinical development for targeting breast cancer; among them, polymeric micelles, microemulsions, magnetic microemulsions, liposomes, dendrimers, carbon nanotubes, and magnetic Nanoparticles (NPs) are the most common. The current review highlights the active and passive targeting potential of nanocarriers in breast cancer and discusses their role in targeting breast cancer without affecting normal healthy cells.
Collapse
Affiliation(s)
- Sivakumar P Malliappan
- Center for Molecular Biology, Institute of Research and Development, Duy Tan University, 03 Quang Trung, Da Nang, Vietnam
| | - Palanivel Kandasamy
- Institute of Biochemistry and Molecular Medicine (IBMM), University of Bern, CH-3012 Bern, Switzerland
| | - Siva Chidambaram
- Department of Physics and Nanotechnology, SRM Institute of Science and Technology, Kattankulathur-603203, India
| | - Devanand Venkatasubbu
- Department of Physics and Nanotechnology, SRM Institute of Science and Technology, Kattankulathur-603203, India
| | - Sathish K Perumal
- Department of Plant Science, Bharathidasan University, Tiruchirappalli, India
| | - Abimanyu Sugumaran
- Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, India
| |
Collapse
|
4
|
Lei M, Sha S, Wang X, Wang J, Du X, Miao H, Zhou H, Bai E, Shi J, Zhu Y. Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer. RSC Adv 2019; 9:5512-5520. [PMID: 35515924 PMCID: PMC9060788 DOI: 10.1039/c9ra00276f] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2019] [Accepted: 02/07/2019] [Indexed: 11/27/2022] Open
Abstract
Multi-functional nanoparticles can be used to improve the treatment index and reduce side effects of anti-tumor drugs. Herein, we developed a kind of multi-functional and highly biocompatible nanoparticle (NP) loaded with folic acid (FA), paclitaxel (PTX) and gemcitabine (GEM) via self-assembly to target cancer cells. The transmission electron microscopy (TEM) results showed that multi-functional FA targeting nanoparticles (MF-FA NPs) exhibited spherical morphology and favorable structural stability in aqueous solution. In addition, NPs (MF-FA NPs and MF NPs) exhibited comparable proliferation inhibition to breast cancer cell 4T1 compared with the pure drug. In in vivo antitumor studies, NPs showed an obviously enhanced anti-tumor efficacy compared with the pure drug. Furthermore, MF-FA NPs displayed higher tumor growth inhibition than MF NPs due to the specific targeting of FA to cancer cells. Consequently, the novel MF-FA NPs could be used as a potential chemotherapeutic formulation for breast cancer therapy. Preparation of MF-FA nanoparticles and the release behavior of drugs in tumor cells.![]()
Collapse
Affiliation(s)
- Meng Lei
- College of Science
- Nanjing Forestry University
- Nanjing 210037
- PR China
| | - Sijia Sha
- College of Science
- Nanjing Forestry University
- Nanjing 210037
- PR China
| | - Xueyuan Wang
- College of Life Science
- Nanjing Normal University
- Nanjing 210046
- PR China
| | - Jia Wang
- Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd
- Nanjing 210046
- PR China
| | - Xiao Du
- Department of Pharmaceutics
- School of Pharmacy
- China Pharmaceutical University
- Nanjing 210009
- PR China
| | - Hang Miao
- College of Science
- Nanjing Forestry University
- Nanjing 210037
- PR China
| | - Hui Zhou
- College of Life Science
- Nanjing Normal University
- Nanjing 210046
- PR China
| | - Enhe Bai
- College of Life Science
- Nanjing Normal University
- Nanjing 210046
- PR China
| | - Jingmiao Shi
- Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd
- Nanjing 210046
- PR China
| | - Yongqiang Zhu
- College of Life Science
- Nanjing Normal University
- Nanjing 210046
- PR China
| |
Collapse
|
5
|
Chen W, Cheng CA, Lee BY, Clemens DL, Huang WY, Horwitz MA, Zink JI. Facile Strategy Enabling Both High Loading and High Release Amounts of the Water-Insoluble Drug Clofazimine Using Mesoporous Silica Nanoparticles. ACS APPLIED MATERIALS & INTERFACES 2018; 10:31870-31881. [PMID: 30160469 DOI: 10.1021/acsami.8b09069] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The use of nanocarriers to deliver poorly soluble drugs to the sites of diseases is an attractive and general method, and mesoporous silica nanoparticles (MSNs) are increasingly being used as carriers. However, both loading a large amount of drugs into the pores and still being able to release the drug is a challenge. In this paper, we demonstrate a general strategy based on a companion molecule that chaperones the drug into the pores and also aids it in escaping. A common related strategy is to use a miscible co-solvent dimethyl sulfoxide (DMSO), but although loading may be efficient in DMSO, this co-solvent frequently diffuses into an aqueous environment, leaving the drug behind. We demonstrate the method by using acetophenone (AP), an FDA-approved food additive as the chaperone for clofazimine (CFZ), a water-insoluble antibiotic used to treat leprosy and multidrug-resistant tuberculosis. AP enables a high amount of CFZ cargo into the MSNs and also carries CFZ cargo out from the MSNs effectively when they are in an aqueous biorelevant environment. The amount of loading and the CFZ release efficiency from MSNs were optimized; 4.5 times more CFZ was loaded in MSNs with AP than that with DMSO and 2300 times more CFZ was released than that without the assistance of the AP. In vitro treatment of macrophages infected by Mycobacterium tuberculosis with the optimized CFZ-loaded MSNs killed the bacteria in the cells in a dose-dependent manner. These studies demonstrate a highly efficient method for loading nanoparticles with water-insoluble drug molecules and the efficacy of the nanoparticles in delivering drugs into eukaryotic cells in aqueous media.
Collapse
|
6
|
Design, synthesis and 3D QSAR based pharmacophore study of novel imatinib analogs as antitumor-apoptotic agents. Future Med Chem 2018; 10:1421-1433. [PMID: 29788766 DOI: 10.4155/fmc-2017-0242] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
AIM Imatinib possesses various mechanisms for combating cancer, making the development of imatinib analogs an attractive target for cancer research. METHOD Two series of analogs were designed and synthesized, maintaining the essential pharmacophoric features in imatinib structure. The synthesized compounds were subjected to cell-based antiproliferative assays against nonsmall lung (A549) and colon cancer cell lines. In addition, flow cytometry cell cycle and caspase-3 colorimetric assays were performed. RESULTS Most compounds showed potent anticancer activity against both cell lines with IC50 = 0.14-5.07 μM. Three compounds demonstrated ability to reinforce cell cycle arrest at G1 stage in a manner similar to imatinib. In addition, they induced apoptosis via activation of caspase-3.
Collapse
|
7
|
Yu J, Sun L, Zhou J, Gao L, Nan L, Zhao S, Peng T, Han L, Wang J, Lu W, Zhang L, Wang Y, Yan Z, Yu L. Self-Assembled Tumor-Penetrating Peptide-Modified Poly(l-γ-glutamylglutamine)–Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma. Bioconjug Chem 2017; 28:2823-2831. [DOI: 10.1021/acs.bioconjchem.7b00519] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jing Yu
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Lei Sun
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Jinge Zhou
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Lipeng Gao
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Lijuan Nan
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Shimin Zhao
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Ting Peng
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Lin Han
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Jing Wang
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Weiyue Lu
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai 201203, P.R. China
| | - Lin Zhang
- Department
of Pharmacy, Shaoxing People’s Hospital, Shaoxing Hospital of ZheJiang University, Shaoxing 312000, P.R. China
| | - Yiting Wang
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Zhiqiang Yan
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| | - Lei Yu
- Institute
of Biomedical Engineering and Technology, Shanghai Engineering Research
Center of Molecular Therapeutics and New Drug Development, School
of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China
| |
Collapse
|